Loading
Chronic Kidney Disease (CKD) / Ramipril (ACE-inhibitor) / Sacubitril / Valsartan · Phase 2/3 Trial
ClinicalTrials.gov · August 13, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a completed Phase 2/3 trial comparing sacubitril/valsartan to ramipril in hospitalized acute decompensated heart failure patients with chronic kidney disease. No results are posted in this registry record; the primary outcome was change in mean eGFR at 12 weeks. Until results are published, the efficacy and safety of sacubitril/valsartan in this population remain undefined.
Phase 2/3, Interventional, Randomized, Parallel, Open label, Treatment purpose. Acute Decompensated Heart Failure (ADHF), Chronic Kidney Disease (CKD); age from 18 Years. Intervention: Sacubitril / Valsartan. Compared with: Ramipril — Active Comparator. n = 515. 2 sites: Egypt.
This is a completed Phase 2/3 trial comparing sacubitril/valsartan to ramipril in hospitalized acute decompensated heart failure patients with chronic kidney disease. No results are posted in this registry record; the primary outcome was change in mean eGFR at 12 weeks. Until results are published, the efficacy and safety of sacubitril/valsartan in this population remain undefined.
Effect sizes, confidence intervals, p-values, and adverse event rates are not stated.
Pending results publication, clinicians should not rely on this registration to guide sacubitril/valsartan use in ADHF with CKD. Once results are available, they may inform dosing and safety decisions in this understudied population.
This is a completed Phase 2/3 interventional trial registration with no posted results; the study design and planned enrollment are clear, but outcomes remain unreported in this registry record.
As stated by the source record.
Quoted from the source exactly as published.
Pending results publication, clinicians should not rely on this registration to guide sacubitril/valsartan use in ADHF with CKD. Once results are available, they may inform dosing and safety decisions in this understudied population.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07023016). This is a study registration, not published results. Lead sponsor: National Heart Institute, Egypt. Recruitment status: COMPLETED. Phase: PHASE2, PHASE3. Study type: INTERVENTIONAL. Enrollment: 515 participants (ACTUAL). Conditions: Acute Decompensated Heart Failure (ADHF), Chronic Kidney Disease (CKD). Interventions: DRUG: Sacubitril / Valsartan; DRUG: Ramipril (ACE-inhibitor). Primary outcome measures: Difference in mean eGFR (mL/min/1.73m2) between both groups at 12 weeks post-randomization. , 12 weeks. Brief summary: Sacubitril/valsartan is an established medication for heart failure. However, data still lags in its use in heart failure patients with chronic kidney disease. Sacubitril/valsartan is manufacturer-labeled for use in patients with eGFR \< 30 ml/min/1.73 m2 at an initial dose of 24/26mg twice daily. However, to the best of our knowledge, the concept of sacubitril/valsartan or ACEi in patients with chronic kidney disease \& presenting with decompensated heart failure has not yet been explored fully.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.